Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference

Kidney International

Volumn 87, Issue 3, 2015, Pages 502-508

  Ketteler, Markus ^a   Elder, Grahame J ^b,c   Evenepoel, Pieter ^d   Ix, Joachim H ^e,f,g   Jamal, Sophie A ^h   Lafage Proust, Marie Hélène ⁱ   Shroff, Rukshana ^j   Thadhani, Ravi I ^k   Tonelli, Marcello A ^l   Kasiske, Bertram L ^m   Wheeler, David C ⁿ   Leonard, Mary B ^o  

^a KLINIKUM COBURG   (Germany)

^b WESTMEAD HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h WOMEN S COLLEGE HOSPITAL   (Canada)

ⁱ Sainbiose   (France)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF ALBERTA   (Canada)

^m HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

calcium; CKD MBD; clinical practice guideline; phosphate; PTH; renal osteodystrophy

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHELATING AGENT; PHOSPHORUS;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE MASS; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; MINERAL DEFICIENCY; MINERAL METABOLISM; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; CLASSIFICATION; COMPLICATION; FRACTURES, BONE; METABOLIC BONE DISEASE; METABOLISM; VASCULAR CALCIFICATION;

BONE DISEASES, METABOLIC; CALCIUM; CALCIUM CHELATING AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION; VITAMIN D;

EID: 84938416638     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.425     Document Type: Conference Paper

References (23)

1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-S130
3. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3): S1-S201
4. Goldsmith DJ, Covic A, Fouque D, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant. 2010; 25: 3823-3831
5. Manns BJ, Hodsman A, Zimmerman DL, et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010; 55: 800-812
6. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the iagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010; 55: 773-799
7. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23: 1407-1415
8. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-Analysis. Nephrol Dial Transplant. 2009; 24: 3168-3174
9. Russo D, Corrao S, Battaglia Y, et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int. 2011; 80: 112-118
10. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012; 7: 487-493
11. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011; 26: 1327-1339
12. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26: 1829-1835
13. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007; 18: 59-68
14. Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-A single-center cohort study. Nephrol Dial Transplant. 2012; 27: 345-351
15. Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012; 7: 1130-1136
16. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-Analysis. Lancet. 2013; 382: 1268-1277
17. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013; 83: 959-966
18. Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6: 257-264
19. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA. 2009; 301: 629-635
20. Bailey DA, Martin AD, McKay HA, et al. Calcium accretion in girls and boys during puberty: a longitudinal analysis. J Bone Miner Res. 2000; 15: 2245-2250
21. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012; 307: 674-684
22. Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial. J Am Soc Nephrol. 2014; 25: 175-186
23. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367: 2482-2494